title: Antibiotic treatment strategies for Helicobacter pylori infection.
abstract: In the third decade of the Helicobacter pylori era several informations are available on its pathogenetic mechanisms, as well as on therapeutic approaches. A 7-14 day triple or quadruple regimens (proton pump inhibitor together with 2 antibiotics) are currently suggested as first-line treatment, but the success rate following these therapy is constantly decreasing worldwide. Therefore, new drugs are needed to treat such a widespread infection. Several patents of new antibiotics have been claimed in the last 5 years, and some of them showed a very powerful antibacterial activity in vitro, even against clarithromycin and metronidazole resistant strains. Among the new compounds, thienylthiazole derivatives, benzamide derivatives and pyloricidins should be regarded as very promising molecules.
authors.affiliation: Gastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital, Rome, Italy. salvatorecampo@yahoo.com
authors.forename: S M A
authors.initials: SM
authors.lastname: Campo
authors.forename: A
authors.initials: A
authors.lastname: Zullo
authors.forename: C
authors.initials: C
authors.lastname: Hassan
authors.forename: S
authors.initials: S
authors.lastname: Morini
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D010330:Patents as Topic; D013276:Stomach Ulcer / Q000188:drug therapy / Q000209:etiology
chemical_list: D000900:Anti-Bacterial Agents